Phase 4 N=79 Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
Microlaryngoscopy · Rigid Bronchoscopy
Primary: Time to Extubation After End of Procedure — 11.06; 10.36 Minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=61 Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
HIV
Primary: Proportion of Patients Free of Treatment Failure (Noncompleter = Failure) at 24 Weeks. — 30; 31; 0; 0 Participants
Phase 4 N=19 Vigor and the LDR in Parkinson Disease
Parkinson Disease
Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min
Phase 4 N=14 A Study to Assess the Adverse Events and Effectiveness of Rapid Acoustic Pulse (RAP) Device for the Appearance of Cellulite in Adult Participants
Cellulite
Primary: Percentage of Before and After Side-by-side Photographs Correctly Identified by At Least 2 of 3 Blinded Reviewers From the Independent Physician Reviewer (IPR) Panel…
Phase 4 N=10 A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16. — 100…
Phase 4 N=20 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Change in Percent Wall Volume (PWV) — 12.3; 3.9 Percent Wall Volume — p=0.22
Phase 4 N=43 Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels
HIV · Hypercholesterolaemia
Primary: Percentage Change From Baseline in Total Cholesterol at 12 Weeks. — 8.7; 21.4 Percentage Change (%) — p=0.003
Phase 4 N=149 Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Primary: Blood Albumin — 4.02 g/L — p=<0.0125
Phase 4 N=620 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
Measles · Rubella · Rubella Syndrome, Congenital
Primary: Percent of Infants Who Were Seropositive After Immunization at 6 Months (Assessed at 9-month Visit) — 94; 94 percentage of infants
Phase 4 N=200 An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer
Breast Cancer
Primary: LVEF Results — -8; -6 LVEF Percentage (%)
Phase 4 N=101 A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Kidney Neoplasms
Primary: Total Number of Participants Experiencing High Grade Immune-Mediated Adverse Events (IMAE) — 2; 1; 2; 1 Participants
Phase 4 N=300 Clinical Study of Lipoic Acid on Ischemic Heart Failure
Ischemic Heart Failure
Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants
Phase 4 N=366 Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
Hyperkalaemia · Heart Failure With Reduced Ejection Fraction
Primary: Participants Who Achieved Response, Defined as Serum Potassium (sK+) Within 3.5 to 5.0 mEq/L, Spironolactone Greater Than or Equal to 25 mg Daily, no Rescue Therapy for…
Phase 4 N=41 Evaluation of Aerosol in a Dental Clinic
Covid19
Primary: Number of Bacterial Colony Forming Units (CFUs) — 47.2; 125.3; 70.7; 116.7 bacterial colony forming units (CFUs)
Phase 4 N=100 Teva Asthma Predictive Analytics Study
Asthma
Primary: Mean Number of Daily Doses of ProAir® Digihaler™ — 0.55 doses per day